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Abstract
Objective: Magnetic seizure therapy (MST) is under development as an alternative to
electroconvulsive therapy (ECT), as it offers reduction in depression symptoms with fewer
adverse cognitive effects. This study examined the feasibility and efficacy of MST versus ECT
in a randomized trial of geriatric patients with severe depression, then compared the
neurophysiological characteristics of seizures induced by MST or ECT and investigated potential
links between seizure expression and therapeutic response.
Method: Six patients (mean age: 64.8) with severe depression were randomized to receive MST
(n=3) or ECT (n=3) until maximal antidepressant effect (mean number of sessions: 14.67).
Depression symptoms were assessed pre- and post-treatment using the Hamilton Rating Scale for
Depression. Neuropsychological tests of verbal ability, visuospatial ability, memory, fluency,
executive functioning, and motor functioning were administered pre- and post-treatment. 64channel electroencephalogram (EEG) recordings were obtained at the start and end of treatment
to capture power during ictal (seizure) and post-ictal periods for delta, theta, alpha, beta, and
gamma frequency bands.
Results: Two ECT and three MST patients achieved remission of depression symptoms. EEG
power and test performance did not differ between treatments. Ictal power and post-ictal
suppression increased from the start to end of treatment in all frequency bands for the responders
but not the non-responder. Increases in gamma ictal power and post-ictal suppression predicted
slowing on a task of visuomotor skill and executive functioning, while increases in beta and theta
ictal power and post-ictal suppression predicted improvement on a task of verbal fluency.
Conclusions: MST continues to show promise as an efficacious and feasible alternative to ECT.
For both MST and ECT, increases in ictal power and post-ictal suppression in all frequency
bands may be indicators of treatment response, and associated with impairments to visuomotor
functioning.
Keywords: Electroconvulsive therapy, magnetic seizure therapy, EEG, ictal power, post-ictal
suppression
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Introduction
Electroconvulsive therapy (ECT) has long been established as an efficacious treatment for severe
depression (Engel & Kayser, 2016; Kho, van Vreeswijk, Simpson, & Zwinderman, 2003). With
a 60% remission rate in adults with depression and about a 50% response rate for treatmentresistant depression, ECT is at least as equally effective as antidepressant medications, especially
for individuals who have undergone multiple medication trials without success (Blumberger,
Hsu, & Daskalakis, 2015). Geriatric patients are preferentially referred for ECT over younger
patients, perhaps due to intolerance to antidepressants, histories of treatment non-response, and
greater probability of having cardiovascular diseases (Dombrovski & Mulsant, 2007). Not only is
ECT considered safer than medication in regards to cardiovascular risk, but there is evidence that
ECT is more effective than pharmacotherapy alone in depressed geriatric patients (Philibert,
Lynch, & Winokur, 1995).

During ECT, small electric currents are passed through the skull and into the brain of the
anesthetized patient in order to trigger a brief seizure. Despite strong support for its efficacy, a
major concern regarding ECT is its adverse cognitive effects, which impact more than 40% of
patients (Engel et al., 2016). These adverse effects include disorientation lasting up to 40
minutes, retrograde and anterograde amnesia, difficulty concentrating, and slowed processing
(Dybedal, Tanum, Sundet, Gaarden, & Bjølseth, 2014). The severity of these cognitive effects
has been associated with advancing age, which is especially relevant to the depressed geriatric
population (Sackeim et al., 2007). There is ongoing debate regarding the chronicity of ECT’s
adverse effects, where one systematic review reported no long-term adverse cognitive effects
lasting more than six months following treatment (Kumar et al., 2016), while another study
reported slowed reaction time and impaired memory at six month follow-up (Sackeim et al.,
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2007). Nevertheless, anecdotal evidence of permanent memory loss raises concerns among
potential patients.

Magnetic seizure therapy (MST) is under development as an alternative to conventional ECT in
the treatment of severe depression. MST uses high frequency repetitive transcranial magnetic
stimulation (rTMS) to induce seizures. A coil placed near the patient’s head generates a magnetic
field that can pass through the scalp and skull to induce a small electric current in the brain. In
2008, rTMS at low frequencies was approved in the U.S. as treatment for depression in
medication non-responders up to 69 years old (NIMH, 2016). rTMS reduces depressive
symptoms with only transient discomfort during stimulation and no cognitive effects
(Blumberger et al., 2015; Loo & Mitchell, 2005). However, its efficacy is lower than that of ECT
(George et al., 2010), and there is little evidence of its efficacy specifically in geriatric
populations. By using higher frequencies of stimulation (> 50 Hz), MST may amplify the
antidepressant effect of rTMS by inducing a seizure similarly to ECT. The development of MST
aims to combine the lower side effect profile of rTMS with the efficacy found from seizure
induction in ECT.

In developing and testing MST, both its efficacy and adverse effects must be considered and
balanced to determine its feasibility as an alternative treatment. In ECT, efficacy and side effects
are both influenced by the site of seizure induction and the extent of stimulation (Sackeim et al.,
2008), which are difficult to control using conventional ECT protocol. There is ongoing debate
regarding the parameters of ECT administration that would best maintain efficacy while
minimizing side effects, such as number and location of stimulation sites, and the importance of
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individual seizure thresholds (Abrams, 2002). However, since the skull has a high impedance, it
shunts electrical current through the scalp and cerebrospinal fluid surrounding the brain,
resulting in widespread stimulation of cortical and subcortical regions regardless of ECT
configuration (Cretaz, Brunoni, & Lafer, 2015). A simulation study showed that standard ECT
configurations can stimulate up to 94% of brain volume at a suprathreshold level, with the
hippocampus being exposed to stimulation in all ECT configurations (Lee, Lisanby, Laine, &
Peterchev, 2016). Subcortical and hippocampal activation during ECT is thought to contribute to
its cognitive side effects.

By contrast, MST uses magnetic stimulation that bypasses the skull, which avoids the issue of
skull impedance and shunting, thus offering better control over the spatial distribution of
stimulation (Cretaz et al., 2015). Both simulations and intracerebral recordings have shown that
MST induces less intense electric fields that are more confined to superficial cortex (Hoy &
Fitzgerald, 2011; Lee et al., 2016; Lisanby, Luber, Schlaepfer, & Sackeim, 2003). With more
confined stimulation, MST offers reduced risk of hippocampal activation, which may result in
fewer memory-related side effects.

The first MST device was a custom rTMS machine and was tested in preclinical trials in 2000,
followed by the first human test in 2001, which resulted in a reduction in depression score
(Lisanby, Schlaepfer, Fisch, & Sackeim, 2001). Since then, several open-label studies have
demonstrated the efficacy of MST and that its antidepressant response was comparable to that of
ECT (Kayser et al., 2011, 2015; Kosel, Frick, Lisanby, Fisch, & Schlaepfer, 2003). In addition,
MST resulted in fewer cognitive side effects and faster reorientation than ECT (Cycowicz,
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Luber, Spellman, & Lisanby, 2009; Kayser, Bewernick, Hurlemann, Soehle, & Schlaepfer, 2013;
Lisanby et al., 2003; Moscrip, Terrace, Sackeim, & Lisanby, 2006). Therefore, MST shows
promise as an efficacious alternative to ECT. However, the mechanism by which they elicit
therapeutic response is still unclear, though there are several hypotheses, including localized
suppression of neural metabolic activity, adaptive changes in monoamine neurotransmitter
systems, regulation of the hypothalamic-pituitary-adrenal axis, and influences on neural
plasticity and neurogenesis (Charney, Menkes, & Heninger, 1981; Merkl, Heuser, & Bajbouj,
2009; Sackeim, Decina, Prohovnik, Malitz, & Resor, 1983).

Examining characteristics of the seizures induced by ECT and MST may improve understanding
of their therapeutic mechanisms by pinpointing properties correlated with antidepressant
response. Electroencephalography (EEG) can be used to measure electrical brain activity at the
scalp level before, during (ictal), and after (post-ictal) seizures. Studies of simultaneous EEGECT have shown that greater total ictal power, delta power, and post-ictal suppression, the
difference between ictal and post-ictal power, are predictive of better response to treatment
(Luber et al., 2000; Mayur, 2006; Nobler et al., 2000; Perera et al., 2004). When comparing the
neurophysiological characteristics of MST and ECT using two-channel EEG in non-human
primates, ECT resulted in significantly greater ictal power and post-ictal suppression for all
frequency bands compared to MST (Cycowicz et al., 2009; Lisanby et al., 2003). However, these
differences may have been due to limitations of the MST and recording equipment, and it is
unknown whether the association between ictal power, post-ictal suppression, and therapeutic
response adheres for MST in humans as well. It may not be necessary to induce as intense of an
electric field or seizure using MST in order to elicit therapeutic effects. In fact, a reduced electric
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field may be advantageous in that the current and the seizure would stay confined to superficial
cortex, reducing the likelihood of generalization to limbic structures involved with memory.
Further exploration of the differences in ictal and post-ictal expression between MST and ECT
and their relation to treatment response may clarify mechanisms of therapeutic action in induced
seizures, and identify seizure parameters to be optimized for efficacy.

Though general neurophysiological characteristics of ECT have been identified, EEG research in
brain stimulation therapies has thus far been limited by technological challenges. Most EEG
studies (Lisanby et al., 2003; Cycowicz et al., 2009) have used passive electrodes, which have no
built-in circuitry and are therefore better able to withstand currents applied from ECT or MST.
However, it is difficult to detect smaller signals with passive electrodes than with active
electrodes, which have built-in circuitry to amplify the signal even before it reaches the
amplifier, thereby improving signal quality dramatically. The downside of active electrodes used
to be their dysfunction when subjected to high input from ECT, MST, or TMS, but that has been
resolved in recent iterations of more durable active electrode caps. Unlike past comparisons of
MST and ECT that used two-channel passive caps, the current study uses a 64-channel active
cap. Recording with a high-density active cap not only results in better signal quality,
particularly for low-amplitude high-frequency oscillations, but it can also show differential ictal
expression from different brain regions.

The current study of MST and ECT has two major goals: First is to evaluate the feasibility and
antidepressant efficacy of MST in elderly patients with severe depression. We hypothesize that
MST will result in a significant decrease in depressive symptoms. Demonstrating the usability of
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MST would further its development as a safer and more favorable alternative treatment to
conventional ECT. The second goal of the current study is to compare the neurophysiological
characteristics of MST and ECT in human patients. In line with findings in non-human primates,
we expect that MST will show lower ictal power and therefore less post-ictal suppression. To
date, this is the first simultaneous high-density EEG-MST study in humans using an active cap.
Investigating both treatments through high-density EEG may provide insight into the
mechanisms by which elicited seizures result in differing therapeutic response in depressed
patients.

Methods
This study was approved by the New York State Psychiatric Institute (NYSPI) Institutional
Review Board.

Participants
Fifteen eligible individuals enrolled in the study and began treatment. Two participants withdrew
from the study prior to completion. Complete sets of EEG recordings were obtained for eight
participants. Two participants’ data were omitted from analyses due to issues with recording. Of
the remaining six participants, five were female. The six participants ranged in age from 57 to 74
years old (mean: 64.8, standard deviation [SD]: 7.41, Table 1).

All participants were between the ages of 55 and 90 and willing and capable of providing
informed consent. Participants were recruited via flyers and brochures at NYSPI, as well as
referral by private physicians and clinical services at NYSPI and other psychiatric facilities.
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Participants were eligible to participate if they had received a clinical diagnosis of a major
depressive episode in the context of unipolar or bipolar disorder, a Hamilton Rating Scale for
Depression (HRSD) score ≥ 20 (indicating severe symptoms of depression), and a Mini Mental
State Exam score ≥ 24 (indicating normal cognition). Outpatients enrolling in the study needed
to be living with a responsible adult to provide support and oversee treatment adherence.
Participants were excluded if they had a history of schizophrenia, schizoaffective disorder, rapid
cycling bipolar disorder, or substance abuse or dependence within the last three months as
determined by the Structured Clinical Interview for Diagnosis (SCID-IV) and a urine toxicology
screen. Participants were also excluded if they had a current unstable or serious medical
condition, or any medical condition that substantially increased the risks associated with MST or
ECT as determined by physician evaluation. Participants with a history of neurological disorder,
epilepsy, stroke, brain surgery, metal in the head, known brain lesions, or moderate to severe
head trauma were excluded due to potential risks associated with MST and ECT. The presence of
devices that may be affected by MST or ECT (e.g. pacemakers, cochlear implants, implanted
brain stimulators, and intracardiac lines) was also a contraindication to treatment. Patients who
had a history of ECT treatment within the past six months or who had failed to respond to a past
adequate trial of ECT were excluded as well.

Procedure
Eligible participants were randomized to receive magnetic seizure therapy (MST) or
electroconvulsive therapy (ECT) treatment. Of the participants included in later analyses, three
received MST and three received ECT. They were masked to which treatment they received.
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Participants assigned to ECT completed a physical exam, blood work, and received medical
clearance in accordance with the NYSPI Policy and Procedure Manual for ECT.

Psychotropic medication washout: In order to determine the efficacy of MST and ECT in the
absence of additional treatment, all participants were washed out from psychotropic medications
for five days prior to treatment with the exception of lorazepam up to 3mg/day. Leading to the
washout period, each participant received a schedule for tapering medications tailored to their
regimen and clinical status.

Motor threshold and seizure titration: To determine the intensity of subconvulsive repetitive
transcranial magnetic stimulation (rTMS) necessary for MST, motor threshold and seizure
threshold were obtained on the first and last treatment sessions. Motor threshold was defined as
the minimum magnetic flux necessary to elicit a 50-microvolt peak to peak electromyography
(EMG) response in five out of ten trials when administering single pulse TMS to the
contralateral primary motor cortex. Seizure threshold was determined using the stimulus titration
and ascending method-of-limits procedure, where increasingly powerful stimuli were applied
until a seizure of adequate duration (≥ 20 seconds) was induced.

Anesthesia: Prior to treatment, all participants were given atropine (0.4 mg i.v.) to prevent postseizure bradycardia, general anesthesia, and succinylcholine (0.75-1.0 mg/kg) as an intravenous
muscle relaxant. Seizure duration was monitored via EEG and motor manifestations. A blood
pressure cuff was placed and inflated on a limb prior to succinylcholine administration to prevent
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exposure to the muscle relaxant to that limb, thus allowing observation of the motor seizure
while reducing risk of injury.

Magnetic seizure and electroconvulsive therapy: MST was administered bilaterally using a
MagPro coil with simultaneous stimulation over the left dorsolateral prefrontal cortex and to the
right of vertex at 5x seizure threshold (MagVenture A/S, Farum, Denmark; 50 Hz, biphasic, 370
µs phase width). Seizure threshold was typically reached at 200 pulses, so that treatment dosage
was 1000 pulses on post-titration treatment days. ECT was right unilateral at 5x seizure threshold
(Thymatron ECT Machine, Somatics, LLC, Lake Bluff, IL; Ultrabrief stimulus – 0.25-0.3ms).
Treatments were administered three times per week, with the number of sessions ranging from 8
to 18 for participants who completed the study (mean: 14.67, SD: 3.78, Table 1). Treatment was
terminated at maximal antidepressant effect, when participants reached their lowest score of
depressive symptoms on the HRSD or showed no further improvement over three subsequent
treatment sessions. Participants that did not show a clinically significant decline in depressive
symptoms were offered standard-of-care inpatient clinical treatment at no cost, as determined by
discussion with their providers.

Measures
Clinical Ratings
The primary clinical outcome measure was the 24-item Hamilton Rating Scale for Depression
(HRSD) (Hamilton, 1960). Typically, scores of 20 or higher on the HRSD are considered
indicative of moderate to severe depression, while scores in the 0-7 range are considered normal.
HRSD scores were obtained through clinician rating at baseline prior to treatment and within

10

seven days after the last session. Response to treatment was indicated by a > 50% decrease in
HRSD score, while remission was indicated by a > 60% decrease or a post-treatment score in the
normal range.

Neuropsychological Assessment
Participants completed a neuropsychological battery prior to treatment and within seven days of
the last session. The battery included measures of verbal ability, visuospatial ability, memory,
fluency, executive functioning, and motor functioning. The extended 57-point Mini Mental State
Exam (MMSE) was administered to assess general cognitive impairment (Stern, Sano, Paulson,
& Mayeux, 1987). The Wide Range Achievement Test (WRAT) was used to assess verbal and
mathematical ability, specifically the ability to read words, comprehend sentences, spell, and
perform calculations (Wilkinson & Robertson, 2006). The Rey-Osterrieth Complex Figure Test
(ROCF) was used to assess visuospatial reasoning, memory, and organization (Rey, 1941).
Participants were asked to recreate a complex line drawing first by copying it and then by
memory. The Buschke Selective Reminding Test, Goldberg Remote Memory Test, and
Autobiographical Memory Index (AMI) were used to assess short-term and long-term memory
storage and retrieval, as they evaluate recall of spoken words, famous people and events, and
diverse personal events, respectively (Buschke, 1973; Goldberg, 1985; Sackeim et al., 1993).
Digit Span Total, the sum of forward and backward, was used to assess working memory, where
participants recalled sequences of digits in the order they were presented and in reverse order
(Wechsler, 2014). The Controlled Oral Word Association Test (COWAT) and the Category
Fluency Test were used to assess verbal fluency, where participants were asked to name as many
words starting with a certain letter or belonging within a certain category as possible within a set
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time period (Ruff, Light, Parker, & Levin, 1996; Lezak, Howieson, & Loring, 1995). The Stroop
task (word only, color only, and color word conditions) was used to assess processing speed and
executive functioning (Lezak et al., 1995). Participants read color words, named the color of the
ink neutral words were printed in, and named the color of the ink of incongruent color words.
The Trail Making Test was used to assess visuomotor and executive functioning, where
participants first connected letters in order that were distributed across the page (Trails A: A, B,
C, etc.). Then, they connected letters and numbers in alternating sets (Trails B: 1, A, 2, B, etc.)
using a single trace (Lezak et al., 1995). The B/A ratio of scores on the Trail Making Test was
used to assess executive functioning beyond the effects of visuomotor skill and search speed
(Martin, Hoffman, & Donders, 2003). The Grooved Pegboard Test was used to assess motor
dexterity in both the dominant and non-dominant hand, where participants inserted keyed pegs
into holes with randomly positioned slots (Roy & Square, 1994). The Buschke Selective
Reminding Test and the ROCF were omitted from analyses due to invalid or missing data.

Electroencephalography: Electroencephalograms (EEG) serve as indirect measures of electrical
activity from the brain taken at the scalp level. Recordings were obtained at the first session posttitration (start) and penultimate or last (end) sessions (BrainAmp MR plus amplifiers with
EasyCap, BrainProducts GmbH, Gilching, Germany). 64-channel EEG was obtained during the
treatment period, as well as during eyes open and eyes closed resting conditions 15 minutes prior
to and 15 minutes following treatment (sampling rate: 500Hz, low cutoff: 0Hz, high cutoff: 250
Hz, online reference electrode: Fpz, ground electrode on left mastoid, no dedicated EOG
channels).
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EEG Pre-processing
64-channel EEG recordings from during treatment sessions were analyzed using BrainVision
Analyzer 2 (BrainProducts GmbH, Gilching, Germany). Recordings were first visually inspected
for channels that stopped recording or showed excessive artifacts, which were removed from
further analysis. Two of eight participants were removed from analysis at this point due to
recording errors that resulted in the omission of ictal or post-ictal periods. When fewer than six
channels needed to be removed and they were distributed across the scalp, they were instead
interpolated as recommended by Picton et al. (2000) using the spherical splines method (Perrin,
Pernier, Bertrand, & Echallier, 1989). All remaining channels were then average referenced and
put through a band-pass filter (0.4-100Hz with 12dB/octave rolloff). Eye blinks and movement
were attenuated using ocular correction independent components analysis. Artifacts were
automatically marked on individual channels following pre-set criteria: 50 µV/ms maximal
gradient, 400 µV in 200ms maximal difference, -300 to 300µV amplitude variation, and 0.5µV
for 100ms minimal activity. The gradient criterion marked large differences between consecutive
sampling points, the difference criterion marked large differences between minimum and
maximum within a sliding window segment, the amplitude criterion marked extreme amplitude
values, and minimal activity marked very low differences between minimum and maximum
values within a segment. In combination, these artifact detection criteria ensured that nonrecording electrodes and noise from movement, muscle contractions, or electrical interference
did not affect further analyses.

Ictal and post-ictal start and end markers were placed according to visual inspection. The ictal
period was defined as the period immediately following ECT or MST stimulation until the end of
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seizure activity as observed in the EEG. Motor observations of seizure duration were used to
guide marker placement. Two post-ictal periods were defined as the two subsequent 10-second
periods following the ictal period.

EEG Analysis
The first 10 seconds of the ictal period were extracted for equivalent duration to the post-ictal
periods. 10 frontal channels were analyzed, five on the left (AF3, F1, F3, F5, FC3) and five on
the right (AF4, F2, F4, F6, FC4) (Figure 1). Previously marked artifacts in the frontal channels
were removed by setting waveform values during the artifact to the value immediately preceding
the artifact in order to produce a flat line with zero slope. All values following the artifact were
then shifted to connect to the new value at the end of the artifact. Though this method is not
commonly used in EEG analysis, it avoids false artifacts that would arise from cutting out
artifacts and splicing together the remaining data, as well as a false low-frequency signal that
would arise from connecting the remaining data with a sloped line.

Ictal and post-ictal periods underwent a 60 Hz notch filter, then a Morlet wavelet transform in a
custom MATLAB script (Lakatos, Chen, O’Connell, Mills, & Schroeder, 2007) to determine
average power within each of five frequency bands (delta: 0.5-4 Hz, theta: 4-8 Hz, alpha: 8-12
Hz, beta: 14-28 Hz, gamma: 30-58 Hz). Power values of zero obtained from artifact removal
were excluded from the averaging, as well as power values greater than two standard deviations
away from the mean for each frequency band. The Morlet wavelet function is a transformation
that decomposes the EEG signal into its constituent frequency components while maintaining the
time domain, unlike fast Fourier transforms (Grossmann & Morlet, 1984). These frequency
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components can then be grouped into bands and their power analyzed at different time points or
averaged across a specified period for each channel. This analysis resulted in average power
values for five frequency bands for each of ten frontal channels within three periods (ictal, postictal 1, and post-ictal 2). These average power values were calculated for each participant at their
start and end treatment sessions.

Power was averaged across channels within each hemisphere, then the hemispheres were
averaged to obtain power values representative of frontal EEG. Post-ictal suppression was
calculated as the difference in power between the ictal period and the first post-ictal period. To
assess change in EEG across the course of treatment, differences in ictal power and post-ictal
suppression between the start session and the end session were calculated.

Statistical Analysis
A repeated-measures ANOVA was used to assess the main effects and interactions of treatment,
session, period, and hemisphere on power (afex, R package version 0.16-1, 2016). Hemisphere
(left or right), session (start or end), and period (ictal, post-ictal 1, or post-ictal 2) were withinsubjects factors while treatment (MST or ECT) was the between-subjects factor. Post-hoc
analyses assessed the direction of main effects and interactions between factors (lsmeans, R
package version 2.26-3, 2016).
Since treatment termination was determined by decrease in HRSD score, treatment duration
varied by participant. Pearson’s correlation analyses assessed the relationship between the
number of treatments and changes in ictal power and post-ictal suppression for the five
frequency bands.
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To examine the relationship between EEG characteristics and performance on
neuropsychological tests, hierarchical/sequential multiple regression analyses were used. Test
performance was first regressed only on treatment (Model 1), then on treatment and change in
ictal power (Model 2a), or treatment and change in post-ictal suppression (Model 2b). ΔR2 from
Model 1 to Model 2 indicated the increased fit of the regression model when considering change
in ictal power or post-ictal suppression after controlling for treatment. Model 2 analyses with
ΔR2 > .7 were investigated further. Finally, the interaction between treatment and change in ictal
power (Model 3a) or change in post-ictal suppression (Model 3b) was added to each
respectively.
Results
Five (2 ECT, 3 MST) of six patients responded to treatment and achieved remission of
depression symptoms as indicated by >60% decrease in HRSD score (Table 1). MST responders
showed a range of 13 to 18 treatment sessions, while ECT responders showed a range of 16 to 18
sessions. Neither treatment nor the number of treatment sessions predicted change in ictal power
or change in post-ictal suppression for any of the frequency bands.
Power did not differ between left and right hemispheres and hemisphere did not interact with
other factors, so power was averaged across hemispheres for the following analyses. The effects
of treatment, session, and period on average frontal power within the five frequency bands for
the five responders were assessed using a repeated-measures ANOVA (Table 2). Power did not
differ by treatment for any of the frequency bands. Power differed by session for theta and alpha,
where the end session showed higher power on average than the start session. Though power did
not significantly differ by period, power during the ictal period tended to be higher than during
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either of the post-ictal periods (Figure 2). There was a significant interaction between session
and period for delta, theta, and alpha bands. Post-hoc analyses indicated that the ictal power was
higher during the end session than the start session, while post-ictal power did not differ across
sessions (Figure 2). By contrast, the non-responder did not show as marked post-ictal
suppression or an increase in ictal power for the end session.
Neuropsychological assessment
Model 1 of hierarchical regression analyses regressed change in test performance from start to
end session on treatment. Treatment did not significantly predict change in test performance for
any tests. Models 2a and 2b predicted test performance from treatment and change in ictal power
or change in post-ictal suppression, respectively. Neither change in ictal power nor post-ictal
suppression predicted change in performance on the Goldberg Remote Memory Test, the
Category Fluency Test, Digit Span, the Autobiographical Memory Index, or the Stroop task,
after controlling for treatment
However, change in ictal power or post-ictal suppression did contribute to change in Trails,
COWAT, and Grooved Pegboard performance. An increase in gamma ictal power or post-ictal
suppression significantly predicted an increase in Trails B/A ratio after controlling for treatment
(Table 3, Model 2; Figure 3). Since the Trails B/A ratio represents executive functioning in
switching sets, an increase in the ratio indicates slowing of cognitive functioning. Thus, larger
increases in gamma ictal power and gamma post-ictal suppression across the course of treatment
were associated with greater impairment of executive functioning.
An increase in beta ictal power or post-ictal suppression also significantly predicted an increase
in COWAT score after controlling for treatment (Table 4, Model 2; Figure 4). An increase in
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theta post-ictal suppression significantly predicted an increase in COWAT score after controlling
for treatment, and there was a trend towards an association between an increase in theta ictal
power and COWAT score (Table 5, Model 2; Figure 5). An increase in COWAT score indicates
improved performance, so increased theta and beta ictal power and theta post-ictal suppression
were associated with improvements in verbal fluency.
An increase in alpha ictal power may be associated with an increase in Grooved Pegboard Nondominant score (Table 6, Model 2a; Figure 6), where an increase in score indicates slowing in
motor performance. The interaction between treatment and change in ictal power or post-ictal
suppression did not contribute to any of the models generated. Therefore, treatment did not
moderate the effect of ictal power or post-ictal suppression on cognitive performance.
Discussion
This study presents the first human neurophysiological findings using high-density EEG
comparing ECT and MST for the treatment of severe depression. The primary finding of this
study involved the differential pattern of ictal expression across the course of treatment between
the responders and the non-responder. All patients showed increased power during the ictal
period than the post-ictal periods, though the small sample size limited statistical significance.
However, ictal power and post-ictal suppression were markedly larger for the responders in all
frequency bands. An interaction between session and period in the responder group indicated a
change in the seizure characteristics across the course of treatment, where seizures at the end of
treatment showed greater power and larger post-ictal suppression than at the beginning of
treatment. This change across treatment was not seen in the non-responder, which suggests that
an increase in ictal power and a corresponding increase in post-ictal suppression may be linked
to therapeutic response. Such a link between global ictal power and post-ictal suppression,
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particularly in the delta band, with therapeutic response has been found in the ECT literature, but
has not yet been generalized to MST or other frequency bands (Engel et al., 2016; Mayur, 2006).
By using an active cap to record quality signal in frequencies up to 60Hz, this study found
patterns of increasing ictal power and post-ictal suppression in higher frequencies as well as in
MST.
Of the six patients with complete data, all of the three MST patients obtained remission of
depression symptoms within 18 sessions, which was a treatment duration similar to that of ECT
response in this study. However, a study of ECT in the elderly reported a mean of 7.3 sessions to
reach remission and typical ECT treatment courses are only 8-12 sessions (Blumberger et al.,
2015; Engel et al., 2016). The longer treatment duration of this study was likely due to the
termination criteria of maximal antidepressant effect such that patients could have met criteria
for remission, then continued to show reduction in depression symptoms for several sessions
before treatment termination. Nevertheless, these results support the antidepressant efficacy of
MST in comparison to ECT in a randomized trial.
In contrast to past research, MST and ECT did not differ in terms of power in either the ictal or
post-ictal periods. Non-human primate and human studies have found that MST results in lower
ictal power and less post-ictal suppression than ECT (Cycowicz et al., 2009; Lisanby et al.,
2003). However, recent development of the MST equipment has allowed for greater output
intensity such that the energy multiplier of the seizure threshold used in MST stimulation more
closely resembles that of ECT. Therefore, differences in ictal power in past literature may have
reflected limitations of MST technology at the time. MST and ECT also did not differ in terms of
their effects on cognitive functioning.
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Change in ictal power and post-ictal suppression across the course of treatment were linked to
changes in cognitive functioning, though the relationships differed between domains of
functioning. Increases in ictal power and post-ictal suppression were linked to slowing on Trails
and Grooved Pegboard, but an improvement in the COWAT. An improvement in
neuropsychological functioning post-treatment was found in another randomized trial of MST vs.
ECT with medium effect sizes for measures of visuospatial learning, but there was a slight
decline in performance for verbal fluency (Kayser et al., 2015). The improvements in cognitive
functioning may have been due to a reversal of baseline cognitive deficits associated with severe
depression. The differences in performance found in this study do not closely replicate those
found by Kayser et al. (2015), but they may be explained in terms of the particular domains of
functioning adversely affected by treatment. Though the second portion of the Trail-Making Test
assesses the ability to alternate sets and monitor performance, it also relies heavily on visual
search and visuomotor skills. The ratio score for Trails is meant to account for the effect of
motor functioning as it considers performance on a simpler visual search task, but it does not
account for the increased demand on visuomotor skills given the larger number of potential
targets to search through and connect. Performance on the Grooved Pegboard test also relies
heavily on visuomotor skills. As the COWAT is administered orally, it does not require any
visual or motor responses. The difference in association between ictal power or post-ictal
suppression and cognitive functioning may reflect treatment’s specific effects on visuomotor
functioning while verbal fluency and other aspects of executive functioning are preserved or
improved.
Though this study presents new findings regarding potential neurophysiological characteristics of
therapeutic response to MST, these results are subject to limitations. Sample size was a major
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limitation to interpreting results involving differences between treatments. Based on estimated
small effect sizes between MST and ECT, power analyses indicated that a sample size of seven
per group would be necessary to better assess the effects of treatment and period on power
(G*Power, Version 3.1, 2014). Lack of an MST non-responder was another limitation, as a nonresponder for comparison to the responder group would provide further evidence to whether the
relationship between therapeutic response and ictal power and post-ictal suppression applies to
MST as well as ECT.
Additional studies should continue to examine neurophysiological characteristics associated with
therapeutic response in MST, and to what extent these relationships match those found in ECT.
Specifically, though this study suggests a general association between higher ictal power and
post-ictal suppression with treatment response, evidence for that link in MST is scarce. It is also
unclear whether the same degree of ictal power and post-ictal suppression as seen in ECT is
necessary for equivalent treatment outcomes. Understanding the neurophysiological
characteristics of seizures linked to treatment response would aid the optimization of ECT and
MST parameters for efficacy.
To present a comprehensive picture of MST as an alternative treatment to ECT for depression,
side effect profiles, particularly cognitive and motor side effects, should be investigated further.
Examining EEG in other areas (e.g. temporal lobe, occipital lobe) may elucidate connections
between seizure expression and the visuomotor side effects found in this study. Beyond the
baseline and post-treatment markers obtained in this study, check-ins during treatment and three
and six months following treatment termination would provide information regarding the time
course of side effects. The feasibility of MST depends on whether it presents fewer, less
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impairing, and less chronic side effects. Thus, neuropsychological outcomes should be assessed
at regular intervals during and after treatment.
Overall, this study demonstrated the efficacy of MST in geriatric patients with severe depression,
and identified patterns of ictal expression that may be indicative of therapeutic response. These
results further support the feasibility and efficacy of MST as an alternative treatment to ECT.
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Figures
Figure 1. Topographic map of ten frontal channels (circled) extracted
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Figure 2. Power during ictal and post-ictal periods for start and end sessions. Error bars indicate
standard error of the mean.
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Figure 3. Relationship between change in Trails B/A ratio score and (a) change in ictal power or
(b) change in post-ictal suppression in the gamma band.

a

b

Figure 4. Relationship between change in COWAT score and (a) change in ictal power or (b)
change in post-ictal suppression in the beta band.
a

b
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Figure 5. Relationship between change in COWAT score and (a) change in ictal power or (b)
change in post-ictal suppression in the theta band.

a

b

Figure 6. Relationship between change in Grooved Pegboard score and change in ictal power in
the alpha band.
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Tables
Table 1. Patient characteristics and treatment response
ID

Sex

Age

4011
4012
4013
4016
4017
4018

M
F
F
F
F
F

74
62
74
63
57
59

Treatment # Sessions
ECT
MST
MST
MST
ECT
ECT

Pre HRSD

18
15
18
13
16
8

27
25
38
34
26
22

Post
HRSD
6
2
8
7
7
20

Status
Responder
Responder
Responder
Responder
Responder
Non-responder

Table 2. Repeated-measures ANOVA to assess effects of treatment, session, period, and their
interactions on average frontal power for five frequency bands (Greenhouse-Geisser corrected)
Delta

Theta

Alpha

Beta

Gamma
F
p

F

p

F

p

F

p

F

p

Treatment

0.06

0.82

0.44

0.56

0.26

0.65

0.39

0.58

0.71

0.46

Session

2.82

0.19

33.81

0.01*

12.59

0.04*

8.16 0.06+

8.47

0.06+

Period

3.92

0.14

2.35

0.22

4.97

0.11

5.55 0.10+

6.30

0.08

0.49

0.02

0.89

0.31

0.62

0.04

0.85

0.01

0.92

0.64

0.27

0.64

0.17

0.71

0.33

0.61

0.53

0.52

0.03*

14.12

0.03*

12.58

0.02*

4.64

0.12

8.23

0.05+

0.10+

1.66

0.29

0.12

0.82

0.27

0.65

0.81

0.44

Treatment x
0.60
Session
Treatment x
0.28
Period
Session x
13.06
Period
Treatment x
Session x 5.60
Period
* p < 0.05, + p ≤ 0.10
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Table 3. Summary of hierarchical regression analysis for treatment and change in EEG (gamma) predicting change in Trails B/A ratio
(N=6)
Model 1
B
SE B β
B
-.12 .57
-.10 .05
.03

Variable
Treatment
Change in EEG
Treatment x EEG
Adjusted R2
-.24
2
F for ΔR
.04
+ p < .10, * p < .05, ** p < .01

Model 2a
SE B β
.15
.04
.003 .98**
.92
58.50**

Model 3a
B
SE B β
.09
.36
.08
.03
.004 .97*
.002 .01
.05
.88
.02

Model 2b
Model 3b
B
SE B β
B
SE B
-.01 .15
-.01
.07
.37
.03
.003
.97** .03
.004
.004
.02
.92
.88
57.99**
.05

β
.06
.96*
.08

Table 4. Summary of hierarchical regression analysis for treatment and change in EEG (beta) predicting change in COWAT score
(N=6)
Model 1
B
SE B β
-6.00 8.62 -.33

Variable
Treatment
Change in EEG
Treatment x EEG
Adjusted R2
-.11
2
F for ΔR
.49
+ p < .10, * p < .05, ** p < .01

Model 2a
Model 3a
B
SE B β
B
SE B β
-5.10 4.72
-.28 -5.15 8.11 -.28
.15
.05
.83* .15
.08
.84
-.001 .11
-.005
.67
.50
10.39*
<.001

Model 2b
Model 3b
B
SE B β
B
SE B
-4.93 4.32
-.27 -5.94 6.89
.14
.04
.85* .15
.07
-.02
.09
.72
.59
13.01*
.05

β
-.33
.92
-.11
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Table 5. Summary of hierarchical regression analysis for treatment and change in EEG (theta) predicting change in COWAT score
(N=6)
Model 1
Model 2a
B
SE B β
B
SE B β
-6.00 8.62 -.33 -8.12 5.59
-.45
.16
.06
.79+

Variable
Treatment
Change in EEG
Treatment x EEG
Adjusted R2
-.11
2
F for ΔR
.49
+ p < .10, * p < .05, ** p < .01

.54
6.73+

Model 3a
B
SE B β
3.38 16.83 .19
.14
.07
.70
.14
.19
.67
.46
.54

Model 2b
B
SE B β
-7.24 4.24 -.40
.11
.03
.86*
.73
13.65*

Model 3b
B
SE B
-6.85 8.26
.11
.05
.004
.07
.60
.004

Table 6. Summary of hierarchical regression analysis for treatment and change in EEG (alpha) predicting change in Grooved
Pegboard Non-dominant score (N=6)
Model 1
Model 2a
B
SE B β
B
SE B β
-5.03 15.40 -.16 7.41 10.17 .24
.27
.09
.93+

Variable
Treatment
Change in EEG
Treatment x EEG
Adjusted R2
-.22
2
F for ΔR
.11
+ p < .10, * p < .05, ** p < .01

.57
8.21+

Model 3a
Model 2b
B
SE B β
B
SE B β
31.37 10.54 1.00+ 5.04 14.10 .16
.12
.08
.41
.17
.10
.76
.29
.11
1.19
.86
.16
7.37
2.82

β
-.38
.84
.03
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